OCULAR THERAPEUTIX, INC

For the period ended Dec 31, 2025. Filed Feb 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 5, 2026

OCUL$6.61-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

(In thousands, except share data)


· · · · · · · Additional · · · · · Total
· · Common Stock · · Paid-in · · Accumulated · · Stockholders’
· · Shares · · Par Value · · Capital · · Deficit · · Equity
Balance at December 31, 2022	77,201,819	$8	$652,213	$(616,842)	$35,379
Issuance of common stock upon exercise of stock options	141,952	—	551	—	551
Issuance of common stock in connection with employee stock purchase plan	290,691	—	851	—	851
Issuance of common stock upon public offering, net of issuance costs	36,934,926	4	117,257	—	117,261
Issuance of common stock upon vesting of restricted stock units	393,805	—	—	—	—
Stock-based compensation expense	—	—	17,825	—	17,825
Net Loss	—	—	—	(80,736)	(80,736)
Balance at December 31, 2023	114,963,193	$12	$788,697	$(697,578)	$91,131
Issuance of common stock upon exercise of stock options	3,112,976	—	14,741	—	14,741
Issuance of common stock in connection with employee stock purchase plan	213,131	—	1,016	—	1,016
Issuance of common stock and pre-funded warrants upon private placement	32,413,560	3	316,350	—	316,353
Issuance of common stock upon exercise of conversion option	5,769,232	1	52,499	—	52,500
Issuance of common stock upon vesting of restricted stock units	1,277,398	—	—	—	—
Stock-based compensation expense	—	—	33,109	—	33,109
Net Loss	—	—	—	(193,506)	(193,506)
Balance at December 31, 2024	157,749,490	$16	$1,206,412	$(891,084)	$315,344
Issuance of common stock upon exercise of stock options	3,721,747	1	20,543	—	20,544
Issuance of common stock in connection with employee stock purchase plan	209,677	—	1,592	—	1,592
Issuance of common stock upon vesting of restricted stock units	1,551,706	—	—	—	—
Issuance of common stock upon exercise of pre-funded warrants	3,237,598	—	—	—	—
Issuance of common stock upon public offering, net of issuance costs	49,457,382	5	539,580	—	539,585
Stock-based compensation expense	—	—	43,184	—	43,184
Net loss	—	—	—	(265,939)	(265,939)
Balance at December 31, 2025	215,927,600	$22	$1,811,311	$(1,157,023)	$654,310

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.